Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
Jean Endicott,1 Henrik Svedsäter,2 Julie C Locklear21Department of Psychiatry, Columbia University, New York, NY; 2AstraZeneca Pharmaceuticals, Wilmington, DE, USABackground: We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported...
Enregistré dans:
Auteurs principaux: | Endicott J, Svedsäter H, Locklear JC |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4c48c3d25c844b1dbba96802ad7b0b38 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
par: El-Khalili N
Publié: (2012) -
The management of schizophrenia: focus on extended-release quetiapine fumarate
par: Peuskens J
Publié: (2011) -
Role of extended release quetiapine in the management of bipolar disorders
par: Rayan K Al Jurdi, et autres
Publié: (2010) -
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
par: Pefura Yone EW, et autres
Publié: (2012) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
par: Mann KV, et autres
Publié: (2014)